Should Methotrexate Solution Be Protected from Light Before Injection?
Yes, methotrexate solution must be protected from light prior to injection. This is an explicit FDA requirement for proper drug handling and storage 1.
FDA Drug Label Requirements
The FDA drug label for methotrexate injection is unequivocal: "PROTECT FROM LIGHT. Retain in carton until time of use" 1. This is a mandatory storage instruction that applies to the lyophilized powder formulation and extends to prepared solutions.
Practical Implementation
When preparing methotrexate for injection:
- Keep vials in their original carton until immediately before use 1
- Once reconstituted or drawn up, minimize light exposure during preparation and transport
- Administer promptly after preparation when possible
Supporting Stability Data
Multiple stability studies confirm the importance of light protection:
- Patient-ready syringes containing 25 mg/mL methotrexate remain stable for up to 12 weeks at temperatures ranging from 4°C to 37°C, but only when protected from light 2
- Similarly, methotrexate solutions for ectopic pregnancy treatment maintained stability for 84 days when stored protected from light 3
- Diluted methotrexate solutions in IV bags (both 0.9% sodium chloride and 5% dextrose) were stable for 28 days at 25°C when protected from light 4
Clinical Significance
Light protection is not merely a theoretical concern—it's a practical requirement to:
- Prevent photodegradation of the active drug
- Maintain therapeutic efficacy
- Ensure patient safety by avoiding administration of degraded product
The consistent requirement for light protection across all formulations and concentrations in both FDA labeling and stability studies makes this a non-negotiable aspect of methotrexate handling 1, 2, 3, 4.